Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Opposing roles of PGD(2) in GSM

Full text
Author(s):
Ferreira, Matthew Thomas [1] ; Gomes, Renata Nascimento [1] ; Panagopoulos, Alexandros Theodoros [2] ; de Almeida, Fernando Gonsalves [3] ; Esteves Veiga, Jose Carlos [2] ; Colquhoun, Alison [1]
Total Authors: 6
Affiliation:
[1] Univ Sao Paulo, Inst Biomed Sci, Dept Cell & Dev Biol, Sao Paulo - Brazil
[2] Santa Casa Hosp, Dept Neurosurg, Sao Paulo - Brazil
[3] Univ Sao Paulo, Inst Biomed Sci, CEFAP, Sao Paulo - Brazil
Total Affiliations: 3
Document type: Journal article
Source: Prostaglandins & Other Lipid Mediators; v. 134, p. 66-76, JAN 2018.
Web of Science Citations: 2
Abstract

Background: The World Health Organization classifies glioblastoma (GBM) as a grade IV astrocytoma. Despite the advances in chemotherapy, surgery, and radiation treatments that improve a patient's length of survival, the overall trajectory of the disease remains unchanged. GBM cells produce significant levels of various types of bioactive lipids. Prostaglandin D-2 (PGD(2)) influences both pro- and anti-tumorigenic activities in the cell; however, its role in GBM is unclear. Therefore, this study aimed to identify the impact of PGD(2) on GBM cell activities in vitro. Methods: First we looked to identify the presence of the PGD(2) synthesis pathway through RT-PCR, immunohistochemistry, and HPLC-MS/MS in three GBM cell lines. Then, to observe PGD(2)'s effects on cell count and apoptosis/mitosis (Hoechst 33342 stain), and migration (Transweli Assay), the cells were treated in vitro with physiological (< 1 mu M) and/or supraphysiological (> 1 mu M) concentrations of PGD(2) over 72 h. HPLC-MS/MS was used to identify the lipid composition of patients with either Grade II/III gliomas or GBM. Results: We identified the presence of endogenous PGD(2) with its corresponding enzymes and receptors. Exogenous PGD(2) both increased cell count (< 1 mu M) and decreased cell count (10 mu M) in a concentration-dependent manner. There were no significant effects on apoptosis. A significant decrease in mitotic activity was seen only in U251MG, and a significant increase was seen in migration with 5 mu M PGD(2) treatments. A very significant increase of PGD(2) was seen from Grade gliomas to GBM. Conclusions: Our study demonstrates that prostaglandin D-2 possesses a dynamic, concentration-dependent effect in GBM cell activities. The increase of PGD(2) production in GBM patients suggests a pro-tumorigenic role of PGD(2) in glioma growth and invasion. Therefore, prostaglandin signaling in GEM requires further investigation to identify new targets for more effective therapies. (AU)

FAPESP's process: 15/08777-0 - Eicosanoids and the biology of gliomas: influence upon cell proliferation and migration and the response to chemotherapeutic drugs
Grantee:Alison Colquhoun
Support Opportunities: Regular Research Grants